2023-10-06 14:00:00
Antibiotic resistance: Phaxiam wants to expand its phage portfolio
Phaxiam Therapeutics, born from the merger between Erytech and Pherecydes, has signed a strategic research partnership with the Lyon biotech Vetophage, a specialist in phages applied to animal health. Created in 2017, Vetophage has a technological platform capable of discovering, identifying and characterizing phages and endolysins (enzymes produced by phages and involved in the destruction of targeted bacteria).
With this agreement, Phaxiam will be able to exercise exclusive licensing options on certain Vetophage phages and endolysins with applications in human health. “We have been following for a long time, and with great interest, the work carried out by the Vetophage teams and we are delighted with this collaboration with a recognized player in the veterinary field, in order to build bridges between phage therapy in animal health and that intended to the man “, welcomed Thibaut Du Fayet, general director of Phaxiam Therapeutics. The program “also allows us to quickly position ourselves in the technological field of endolysins, which are highly complementary to phages in the clinical applications that we carry out”he stressed.
VOS INDICES
source
Abivax plans to go public
The Parisian biotech, already listed on the Euronext market in Paris, announced the filing of a registration document with a view to its IPO in the form of ADS (American Depositary Shares) in the USA. At this time, neither the number of common shares nor the price range have been determined. This operation is intended to support the development of its flagship drug candidate, obefazimod, once morest ulcerative colitis (or UC), currently in phase III.
Novartis plans to sell radiopharmaceuticals
According to information from Bloomberg, the Swiss laboratory would consider selling part of its radiopharmaceutical portfolio. These products are grouped within Advanced Accelerator Applications, the French laboratory purchased by Novartis in 2018. The planned sale of assets would concern products intended for diagnostics. The Swiss group is seeking to prioritize certain therapeutic areas and had, for example, sold ophthalmology assets to Bausch + Lomb last June.
Selected for you
1696635687
#Phaxiam #Abivax #Novartis
